Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 7:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 130 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Postmenopausal Osteoporosis
Interventions
Not listed
Lead sponsor
Warner Chilcott
Industry
Eligibility
Female only
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
7
States / cities
Palm Desert, California • Lakewood, Colorado • Decatur, Georgia + 4 more
Conditions
Osteoporosis, Post-Menopausal
Interventions
raloxifene, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
55 Years and older · Female only
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
5
States / cities
La Jolla, California • Menlo Park, California • Oakland, California + 2 more
Conditions
Low Bone Density, Osteopenia, Osteoporosis, Postmenopausal
Interventions
Strontium L-lactate
Dietary Supplement
Lead sponsor
BioLink Life Sciences, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Addison, Illinois
Conditions
Post-menopausal Osteoporosis
Interventions
Placebo, Zoledronic acid
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
65 Years and older · Female only
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
10
States / cities
San Diego, California • Lakewood, Colorado • Gainesville, Georgia + 7 more
Recruiting Not applicable Interventional Accepts healthy volunteers

Prunes Preventing Bone Loss in Perimenopause

NCT07120997
Conditions
Perimenopausal Bone Loss
Interventions
Prunes, Calcium supplement, Vitamin D Supplement
Dietary Supplement
Lead sponsor
Penn State University
Other
Eligibility
44 Years to 55 Years · Female only
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
University Park, Pennsylvania
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

Effect of Blueberries on Bone Turnover

NCT02630797
Conditions
Osteoporosis, Postmenopausal, Bone Loss, Age-related
Interventions
Blueberry Baseline, Blueberry Low, Blueberry Medium, Blueberry High
Dietary Supplement
Lead sponsor
Purdue University
Other
Eligibility
45 Years to 70 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
West Lafayette, Indiana
Conditions
Postmenopausal Osteoporosis
Interventions
risedronate
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
50 Years and older · Female only
Enrollment
923 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
20
States / cities
Birmingham, Alabama • Oakland, California • San Diego, California + 16 more
Conditions
Osteoporosis
Interventions
ALX1-11 50 mcg, placebo, ALX1-11 75mcg, ALX1-11
Drug
Lead sponsor
Shire
Industry
Eligibility
50 Years to 75 Years · Female only
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 1997
U.S. locations
15
States / cities
Peoria, Arizona • Loma Linda, California • Mill Valley, California + 12 more
Conditions
Primary Hyperparathyroidism, Osteoporosis, Postmenopausal
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
50 Years to 100 Years · Female only
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Postmenopausal Osteoporosis
Interventions
Ibandronate
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
Female only
Enrollment
1,711 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
142
States / cities
Birmingham, Alabama • Columbiana, Alabama • Huntsville, Alabama + 128 more
Conditions
Osteoporosis, Osteopenia
Interventions
Virtual Bone Biopsy, Teriparatide, Zoledronic Acid
Other · Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
60 Years and older · Female only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Osteoporosis
Interventions
Zoledronic Acid, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
68 Years to 90 Years · Female only
Enrollment
2,456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
30
States / cities
Tucson, Arizona • Little Rock, Arkansas • Beverly Hills, California + 26 more
Completed Phase 1 Interventional Accepts healthy volunteers

Patient- and Physician-Based Osteoporosis Education

NCT00073190
Conditions
Osteoporosis, Osteoporosis, Postmenopausal
Interventions
Osteoporosis Education
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
65 Years and older
Enrollment
30,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Osteoporosis Postmenopausal
Interventions
Risedronate (HMR4003)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
50 Years and older · Female only
Enrollment
1,231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Bridgewater, New Jersey
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Blosozumab (LY2541546) in Postmenopausal Female Participants

NCT02109042
Conditions
Osteoporosis, Postmenopausal
Interventions
Blosozumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
60 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
2
States / cities
Daytona Beach, Florida • Dallas, Texas
Completed Phase 3 Interventional Results available

A Study of Monthly Risedronate for Osteoporosis

NCT00247273
Conditions
Postmenopausal Osteoporosis
Interventions
risedronate
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
50 Years and older · Female only
Enrollment
1,294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
7
States / cities
Lakewood, Colorado • Gainesville, Georgia • Bethesda, Maryland + 4 more
Conditions
Postmenopausal Osteoporosis
Interventions
abaloparatide, abaloparatide solid microstructured transdermal system
Combination Product
Lead sponsor
Radius Health, Inc.
Industry
Eligibility
50 Years to 85 Years · Female only
Enrollment
511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
77
States / cities
Birmingham, Alabama • Anchorage, Alaska • Glendale, Arizona + 65 more
Completed No phase listed Observational Accepts healthy volunteers

Fosamax Bone Loss Study: Alendronate to Prevent Bone Loss

NCT00221312
Conditions
Perimenopausal Bone Loss
Interventions
Fosamax
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
40 Years to 54 Years · Female only
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2007
U.S. locations
1
States / cities
San Francisco, California
Conditions
Postmenopausal Osteoporosis
Interventions
RGB-14-P, Prolia®
Drug
Lead sponsor
Gedeon Richter Plc.
Industry
Eligibility
60 Years to 90 Years · Female only
Enrollment
473 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
4
States / cities
Miami, Florida • Miami Lakes, Florida • Decatur, Georgia + 1 more
Conditions
Postmenopausal Women With Osteoporosis
Interventions
Romosozumab, Alendronate, Placebo to Romosozumab, Placebo to Alendronate
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
55 Years to 90 Years · Female only
Enrollment
4,093 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
32
States / cities
Birmingham, Alabama • Peoria, Arizona • Phoenix, Arizona + 29 more
Conditions
Osteoporosis, Osteopenia or Osteoporosis, Osteoporosis, Postmenopausal, Osteoporosis Risk, Osteoporotic Fractures, Fragility Fracture, Bone Fracture
Interventions
Cortical Bone Mechanics Technology
Diagnostic Test
Lead sponsor
Ohio University
Other
Eligibility
50 Years to 80 Years · Female only
Enrollment
394 participants
Timeline
2022 – 2023
U.S. locations
5
States / cities
Gainesville, Florida • Jacksonville, Florida • Tampa, Florida + 2 more
Conditions
Postmenopausal Osteoporosis, Osteoporosis
Interventions
synthetic hPTH 1-34
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
46 Years to 85 Years · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Postmenopausal Osteoporosis
Interventions
Romozosumab, Teriparatide
Drug
Lead sponsor
Amgen
Industry
Eligibility
55 Years to 90 Years · Female only
Enrollment
436 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
5
States / cities
Gainesville, Georgia • Bethesda, Maryland • Boston, Massachusetts + 1 more
Conditions
Postmenopausal Osteoporosis
Interventions
Ibandronate
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
Female only
Enrollment
545 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
60
States / cities
Montgomery, Alabama • Lake Havasu City, Arizona • Paradise Valley, Arizona + 53 more